Discovery May Help Prevent HIV "Reservoirs" From Forming
Source Newsroom: Albert Einstein College of Medicine of Yeshiva University
Newswise — April 17, 2013 — (BRONX, NY) — Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the protein that blocks HIV-1 from multiplying in white blood cells is regulated. HIV-1 is the virus that causes AIDS, and the discovery could lead to novel approaches for addressing HIV-1 “in hiding” – namely eliminating reservoirs of HIV-1 that persist in patients undergoing antiretroviral therapy. The study was published today in the online edition of the journal Cell Host & Microbe.
Antiretroviral therapy can reduce blood levels of HIV-1 until they are undetectable. But despite drug therapy, reservoirs of HIV-1 can persist in several types of white cells, notably macrophages – important immune cells that help clear pathogens and other potentially harmful substances from the body.
“If you stop antiretroviral therapy, the virus emerges from these reservoirs and returns to the general circulation in a matter of days, as if the patient had never been treated,” said senior author Felipe Diaz-Griffero, Ph.D., assistant professor of microbiology & immunology at Einstein. “Now we know the protein that we need to control so we can prevent HIV-1 reservoirs from forming or eliminate them entirely.”
Scientists have known that a protein called SAMHD1 prevents HIV-1 from replicating in certain immune cells. But until now, it was not understood why SAMHD1 fails to function in immune cells like macrophages that are vulnerable to HIV-1 infection.
Using mass spectrometry, a tool for determining molecular composition, Dr. Diaz-Griffero found that SAMHD1 can exist in two configurations known as phosphorylated and unphosphorylated. (Phosphorylation is an important cellular process in which phosphate groups attach to other molecules, thereby activating various signaling and regulatory mechanisms within the cell.) When SAMHD1 is phosphorylated – the situation in immune cells that divide – the cell is not protected from being infected with HIV-1. When the protein is not phosphorylated – as occurs in the nondividing macrophages – the cell is protected from HIV infection.
“We are currently exploring ways to keep this protein unphosphorylated so that HIV reservoirs will never be formed,” said Dr. Diaz-Griffero.
The title of the paper is “The Retroviral Restriction ability of SAMHD1 is Regulated by Phosphorylation.” Other Einstein contributors are Tommy E. White; Alberto Brandariz-Nuñez, Ph.D.; Jose Carlos Valle-Casuso, Ph.D.; and Marina Tuzova. Additional authors include Sarah Amie, Ph.D.; Laura Nguyen, Ph.D.; and Baek Kim, Ph.D., all at the University of Rochester School of Medicine and Dentistry, Rochester, NY.
The study was funded by a grant (AI087390) from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
The authors declare no conflict of interest.
About Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2012-2013 academic year, Einstein is home to 742 M.D. students, 245 Ph.D. students, 116 students in the combined M.D./Ph.D. program, and 360 http://www.einstein.yu.edu/research/belfer-institute/default.aspx?id=28561&ekmensel=15074e5e_4074_4116_btnlink. The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its clinical affiliates. In 2012, Einstein received over $160 million in awards from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center –Einstein’s founding hospital, and five other hospital systems in the Bronx, Manhattan, Long Island and Brooklyn, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit www.einstein.yu.edu and follow us on Twitter @EinsteinMed.